BY THE ASSOCIATED PRESS: U.S. regulators on Tuesday approved a new diabetes drug that reduces blood sugar levels and also helps people lose significant weight. Danish drugmaker Novo Nordisk said the Food and Drug Administration approved its once-a-week shot for people with. The drug, Ozempic, also known as semaglutide, works by stimulating the body’s own insulin production and reducing appetite.
In one big company-funded study, Ozempic, on average, reduced long-term (read more)at least 2 ½ times as much as a popular daily diabetes pill, Merck & Co.’s Januvia. It also helped study participants lose two to three times as much weight as those in the comparison group.
BY CONSTANCE GIBBS: Type 2 diabetes may not have to last forever.
A clinical trial has shown that a reversal of type 2 diabetes is possible by following an extremely low-calorie diet.
The trial, done at the Magnetic Resonance Center at Newcastle University in the United Kingdom, looked at 306 participants recently diagnosed with type 2 diabetes in the last six years. (read more)
BY JODY A. CHARNOW: Women who have postmenopausal vasomotor symptoms (VMS), especially night sweats, have a higher risk for type 2 diabetes, according to a study published December 6 in Menopause. Further, the excess risk increased with the severity and duration of women’s symptoms, the researchers found.
“The most plausible and consistent explanation may be through associations with sleep disturbance,” write Kristen E. Gray, PhD, from the Veterans Affairs Puget Sound Health Care System and the University of Washington School of Public Health in Seattle, and colleagues. “VMS overall are associated with objective and subjective sleep disturbance, and individuals with disruptions in both the quantity and quality of sleep have a higher risk of diabetes.” (read more)
BY KATHY KEATLEY GARVEY: An international team of scientists led by Professor Ingrid Fleming of Goethe University, Frankfurt, Germany, and including Professor Bruce Hammock of the University of California, Davis, provides new insight into the mechanism by which diabetes leads to retinopathy and often to blindness.
An inhibitor to the enzyme, soluble epoxide hydrolase (sEH), discovered in the Hammock lab, prevented the eye disease in diabetic mice, Fleming said.
The paper, “Inhibition of Soluble Epoxide Hydrolase Prevents Diabetic Retinopathy,” involving six years of research and 22 scientists, is published today (Dec. 6) in the journal Nature. (read more)
BY JESSICA MIGALA: Your skin is a window into the health of your insides—check out all the conditions your skin can reveal. Diabetes is no exception. The back of your neck, groin, or underarms may look “dirty,” but the dark, velvety patches in these areas are actually a symptom of insulin resistance. It’s called acanthosis nigricans (AN). “The hormones involved in insulin resistance are also thought to contribute to the skin condition,” says Margaret Eckert-Norton, RN, PhD, CDE, chair of the Endocrine Society‘s Advocacy and Public Outreach Core Committee and associate professor at St. Joseph’s College in New York City. “It’s something that tends to happen gradually over the years,” she adds. Treatment for AN involves addressing the underlying cause—in this case, regaining control over blood sugar levels. If you have diabetes and you’re looking to reverse, check out this step-by-step plan. (read more)